JP Morgan Chase
STLN

JP Morgan Chase’s Starling Oncology STLN Stock Holding History

JP Morgan Chase’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29M Buy
409,348
+39,171
+11% +$165K ﹤0.01% 4098
2026
Q1 		$1.05M Sell
370,177
-16,601
-4% -$50.9K ﹤0.01% 4583
2025
Q4 		$1.38M Buy
386,778
+362,349
+1,483% +$1.34M ﹤0.01% 4385
2025
Q3 		$85.3K Sell
24,429
-3,506
-13% -$12K ﹤0.01% 5989
2025
Q2 		$57.3K Buy
27,935
+27,881
+51,631% +$69.7K ﹤0.01% 5865
2025
Q1 		$62 Sell
54
-112
-67% -$87 ﹤0.01% 6948
2024
Q4 		$51 Sell
166
-5
-3% -$1 ﹤0.01% 7130
2024
Q3 		$56 Buy
171
+1
+0.6% – ﹤0.01% 7101
2024
Q2 		$78 Sell
170
-8,596
-98% -$7.34K ﹤0.01% 6941
2024
Q1 		$13.8K Buy
8,766
+8,646
+7,205% +$16.4K ﹤0.01% 6292
2023
Q4 		$245 Buy
120
+20
+20% +$35 ﹤0.01% 7030
2023
Q3 		$140 Buy
100
+58
+138% +$60 ﹤0.01% 6877
2023
Q2 		$23 Sell
42
-27,497
-100% -$14.5K ﹤0.01% 6783
2023
Q1 		$19K Buy
27,539
+7,801
+40% +$9.95K ﹤0.01% 5987
2022
Q4 		$32K Buy
19,738
+875
+5% +$2.46K ﹤0.01% 5749
2022
Q3 		$87K Buy
18,863
+8,822
+88% +$51.9K ﹤0.01% 5347
2022
Q2 		$51K Buy
10,041
+9,641
+2,410% +$70.2K ﹤0.01% 5651
2022
Q1 		$3K Sell
400
-3,400
-89% -$22.9K ﹤0.01% 6387
2021
Q4 		$37K Sell
3,800
-457,820
-99% -$4.07M ﹤0.01% 6045
2021
Q3 		$4.58M Sell
461,620
-100
-0% -$993 ﹤0.01% 3111
2021
Q2 		$4.59M Sell
461,720
-64,400
-12% -$648K ﹤0.01% 3129
2021
Q1 		$5.24M Sell
526,120
-73,880
-12% -$787K ﹤0.01% 2936
2020
Q4 		$6.48M Sell
600,000
-100
-0% -$1.03K ﹤0.01% 2590
2020
Q3 		$6.23M Buy
+600,100
New +$6.23M ﹤0.01% 2382

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase's STLN Position: Q2 2026 in Review

JP Morgan Chase increased its Starling Oncology (STLN) stake by 11% in Q2 2026, buying an estimated $165K and bringing the position to 409,348 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #4098.

JP Morgan Chase first reported a position in STLN in Q3 2020 and has held it in 24 quarters since. The position peaked at $6.48M in Q4 2020. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • JP Morgan Chase held 409,348 shares of Starling Oncology worth $2.29M as of Q2 2026.
  • JP Morgan Chase bought 39,171 Starling Oncology shares in Q2 2026, an estimated $165K.
  • Starling Oncology made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4098 holding.
  • JP Morgan Chase first reported a position in Starling Oncology in Q3 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Starling Oncology position peaked at $6.48M in Q4 2020.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.